238
Participants
Start Date
February 29, 2004
Primary Completion Date
November 30, 2006
Study Completion Date
November 30, 2006
Inhaled Corticosteroid (Budesonide)
Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
Leukotriene Receptor Antagonist (Montelukast Sodium)
Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
Inhaled Albuterol
All participants will receive inhaled albuterol treatments four times a day.
Dept. of Health Evaluation Sciences, Penn State College of Medicine, Hershey
University of Wisconsin - Madison, Madison
Washington University School of Medicine Patient Oriented Research Unit, St Louis
National Jewish Medical and Research Center, Denver
University of Arizona, College of Medicine, Tucson
UCSD School of Medicine, La Jolla
National Heart, Lung, and Blood Institute (NHLBI)
NIH